Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24884203 | 1.00 | KDM4E (0.36) | KDM4ECSNK2A1CCR1SLC6A2SLC6A4 | |
| SCHEMBL24884325 | 1.00 | KDM4E (0.36) | KDM4ECSNK2A1CCR1SLC6A2SLC6A4 | |
| SCHEMBL20462621 | 0.85 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24884259 | 0.84 | CSNK2A1 (0.35) | KDM4ECSNK2A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24884189 | 0.84 | CSNK2A1 (0.35) | KDM4ECSNK2A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22259384 | 0.80 | SLC6A2 (0.33) | CCR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2185532 | 0.77 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3980290 | 0.76 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18214837 | 0.76 | NOS1 (0.41) | KDM4ECSNK2A1PTGS1PTGS2 | |
| SCHEMBL23052795 | 0.75 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10487068-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10487068-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | KDM4E 3081/4885CSNK2A1 445/4885CCR1 119/4885 |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | KDM4E 3081/4885CSNK2A1 445/4885CCR1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.